Abstract

BackgroundCost-effectiveness acceptability curves (CEACs) describe the probability that a new treatment or intervention is cost-effective. The net benefit regression framework (NBRF) allows cost-effectiveness analysis to be done in a simple regression framework. The objective of the paper is to illustrate how net benefit regression can be used to construct a CEAC.MethodsOne hundred patients referred for ambulatory monitoring with syncope or presyncope were randomized to a one-month external loop recorder (n = 49) or 48-hour Holter monitor (n = 51). The primary endpoint was symptom-rhythm correlation during monitoring. Direct costs were calculated based on the 2003 Ontario Health Insurance Plan (OHIP) fee schedule combined with hospital case costing of labour, materials, service and overhead costs for diagnostic testing and related equipment.ResultsIn the loop recorder group, 63.27% of patients (31/49) had symptom recurrence and successful activation, compared to 23.53% in the Holter group (12/51). The cost in US dollars for loop recording was $648.50 and $212.92 for Holter monitoring. The incremental cost-effectiveness ratio (ICER) of the loop recorder was $1,096 per extra successful diagnosis. The probability that the loop recorder was cost-effective compared to the Holter monitor was estimated using net benefit regression and plotted on a CEAC. In a sensitivity analysis, bootstrapping was used to examine the effect of distributional assumptions.ConclusionThe NBRF is straightforward to use and interpret. The resulting uncertainty surrounding the regression coefficient relates to the CEAC. When the link from the regression's p-value to the probability of cost-effectiveness is tentative, bootstrapping may be used.

Highlights

  • Cost-effectiveness acceptability curves (CEACs) describe the probability that a new treatment or intervention is cost-effective

  • The net benefit regression framework (NBRF) was implemented by estimating with ordinary least squares (OLS) the regression nbi = β0 + β1LOOP + ε where LOOP is an indicator variable equaling one if the patient received a loop recorder and zero if the patient received a Holter monitor

  • For λ < $1000, the estimate of the incremental net benefit is negative (i.e., b1 < 0), so the quantity to calculate for the CEAC's vertical axis is one half

Read more

Summary

Introduction

Cost-effectiveness acceptability curves (CEACs) describe the probability that a new treatment or intervention is cost-effective. Out patient ambulatory monitoring is often performed in patients with syncope (e.g., fainting or passing out) that present in the primary care setting to diagnose or exclude an arrhythmia, a potentially serious etiology [1,2,3,4,5,6]. This short-term monitoring device may take the form of an (page number not for citation purposes). After a primary diagnostic trial [5], we sought to establish the cost of investigation of "community-acquired" syncope and to evaluate the costeffectiveness of the two monitoring strategies in a prospective randomized trial [20]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call